Our findings demonstrate that tumor-infiltrating NKG2A+ CD8+ T cells are the predominant subset of NKG2A+ cells in human non-small cell lung carcinoma (NSCLC) and suggest that targeting NKG2A+ CD8+ T cells is a promising approach for immunotherapy. Here, KLRC1 is linked to neoplasm.